Key result
Pravastatin daily reduced all-cause mortality compared to placebo over 5 to 6 years in patients with and without coronary heart disease.
Why the study?
Does pravastatin 40 mg daily reduce all-cause and coronary mortality in patients with and without coronary heart disease?
Meta-Analysis (n=19,768)
Yes
Does pravastatin 40 mg daily reduce all-cause and coronary mortality in patients with and without coronary heart disease?
Pravastatin 40 mg daily over 5-6 years significantly reduces all-cause and coronary mortality across a broad range of cholesterol levels in patients with and without prior coronary heart disease.
Answers are grounded in this paper and cite their sources.
Supports statin use to reduce mortality in primary and secondary prevention; reinforces benefits across broad cholesterol levels in randomized evidence.
AIMS: To assess the effects of pravastatin on all-cause mortality and cause-specific mortality and to compare the effects for patients with prior coronary heart disease with those for patients without, using pooled data from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, the Cholesterol and Recurrent Events (CARE) study, and the West of Scotland Coronary Prevention Study (WOSCOPS). METHODS AND RESULTS: 13 173 patients with coronary heart disease and 6595 men with elevated cholesterol and no prior coronary disease received pravastatin, 40 mg daily, or placebo for an average of 5 to 6 years. Data were analysed according to a pre-specified, published protocol. For all three trials combined, the mortality among patients assigned pravastatin was significantly lower, at 7.9%, than the 9.8% among those assigned placebo, a relative risk reduction of 20% (95% confidence interval (CI) 12-27%, P<0.0001). Active treatment was associated with a reduction in coronary mortality (24%, 95% CI 14-33%). Larger reductions in absolute risk were estimated in those with prior coronary heart disease than in those without. CONCLUSION: Treatment with pravastatin over 5 years reduces all-cause mortality and coronary mortality in patients with and those without a history of coronary heart disease. The size of the benefit was related principally to the baseline risk.
No takes yet. Share an insight, caveat, or question.
John Simes (2002) conducted a meta-analysis in Coronary heart disease or elevated cholesterol (n=19,768). Pravastatin vs. Placebo was evaluated on all-cause mortality (RRR 20%, 95% CI 12-27, p=<0.0001). Pravastatin daily reduced all-cause mortality compared to placebo over 5 to 6 years in patients with and without coronary heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: